Commentary on ‘Spontaneous multiple cervical artery dissections after alemtuzumab’

Abstract

Keywords

Alemtuzumab multiple sclerosis side effects stroke carotid dissection

Get full access to this article

View all access options for this article.

References

Tuohy

Costelloe

Hill-Cawthorne

, et al. Alemtuzumab treatment of multiple sclerosis: Long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015; 86(2): 208–215.

https://www.fda.gov/Drugs/DrugSafety/ucm624247.htm

Durand-Dubief

Marignier

Berthezene

, et al. Spontaneous multiple cervical artery dissections after alemtuzumab. Mult Scler 2020; 26: 381–383.

Debette

Leys

Cervical-artery dissections: Predisposing factors, diagnosis, and outcome. Lancet Neurol 2009; 8(7): 668–678.

Richards

Surks

, et al. Clinical pharmacology of alemtuzumab, an anti-CD52 immunomodulator, in multiple sclerosis. Clin Exp Immunol 2018; 194(3): 295–314.

Ulbricht

Diederich

Hermanns-Le

, et al. Cervical artery dissection: An atypical presentation with Ehlers-Danlos-like collagen pathology. Neurology 2004; 63(9): 1708–1710.

Arnold

DeMarchis

Stapf

, et al. Triple and quadruple spontaneous cervical artery dissection: Presenting characteristics and long-term outcome. J Neurol Neurosurg Psychiatry 2009; 80(2): 171–174.

Bejot

Daubail

Debette

, et al. Incidence and outcome of cerebrovascular events related to cervical artery dissection: The Dijon Stroke Registry. Int J Stroke 2014; 9(7): 879–882.